New antiarrhythmic drugs for prevention of atrial fibrillation

Progress in Cardiovascular Diseases

Volumn 48, Issue 3, 2005, Pages 193-208

  Goldstein, Robert N ^a   Stambler, Bruce S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; AZD 7009; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PIBOSEROD; PROCAINAMIDE; PROPAFENONE; RS 100302; SEROTONIN ANTAGONIST; SODIUM CHANNEL BLOCKING AGENT; STEROID; SWD WAG 994; TECADENOSON; TEDISAMIL; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANTICOAGULATION; ARRHYTHMOGENESIS; CARDIOVERSION; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; LIVER DYSFUNCTION; LUNG TOXICITY; MORTALITY; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PRESCRIPTION; QT PROLONGATION; RECURRENT DISEASE; RELAPSE; REVIEW; SUSTAINED RELEASE FORMULATION; TASTE DISORDER; THYROID DISEASE; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 27644457108     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2005.06.013     Document Type: Article

References (88)

1. M.D. Ezekowitz Atrial fibrillation: The epidemic of the new millennium Ann. Intern. Med. 131 1999 537 538
2. H.J. Wellens Atrial fibrillation-the last big hurdle in treating supraventricular tachycardia N. Engl. J. Med. 331 1994 944 945
3. S. Levy, G. Breithardt, and R.W. Campbell Atrial fibrillation: Current knowledge and recommendations for management. Working group on arrhythmias of the European Society of Cardiology Eur. Heart J. 19 1998 1294 1320
4. AFFIRM First Antiarrhythmic Drug Substudy Investigators maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug J. Am. Coll. Cardiol. 42 2003 20 29
5. S.D. Corley, A.E. Epstein, and J.P. DiMarco Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study Circulation 109 2004 1509 1513
6. E.S. Kaufman, P.A. Zimmermann, and T. Wang Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: A multivariate analysis J. Am. Coll. Cardiol. 44 2004 1276 1282
7. J.S. Wilson, and P.J. Podrid Side effects from amiodarone Am. Heart J. 121 1991 158 171
8. P.J. Podrid Amiodarone: Reevaluation of an old drug Ann. Intern. Med. 122 1995 689 700
9. M.C. Wijffels, C.J. Kirchhof, and R. Dorland Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 1995 1954 1968
10. D.R. Van Wagoner, and J.M. Nerbonne Molecular basis of electrical remodeling in atrial fibrillation J. Mol. Cell Cardiol. 32 2000 1101 1117
11. S. Nattel Atrial electrophysiological remodeling caused by rapid atrial activation: Underlying mechanisms and clinical relevance to atrial fibrillation Cardiovasc. Res. 42 1999 298 308
12. Y. Blaauw, H. Gogelein, and R.G. Tieleman "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat Circulation 110 2004 1717 1724
13. D. Li, A. Benardeau, and S. Nattel Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation Circulation 102 2000 104 112
14. R.G. Tieleman, C. De Langen, and I.C. Van Gelder Verapamil reduces tachycardia-induced electrical remodeling of the atria Circulation 95 1997 1945 1953
15. S.H. Lee, W.C. Yu, and J.J. Cheng Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling Circulation 101 2000 200 206
16. S. Fareh, A. Benardeau, and S. Nattel Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs Cardiovasc. Res. 49 2001 762 770
17. D. Li, S. Fareh, and T.K. Leung Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort Circulation 100 1999 87 95
18. O.D. Pedersen, H. Bagger, and L. Kober Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
19. D. Li, K. Shinagawa, and L. Pang Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
20. Y. Shi, D. Li, and J.C. Tardif Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure Cardiovasc. Res. 54 2002 456 461
21. A.H. Madrid, M.G. Bueno, and J.M. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study Circulation 106 2002 331 336
22. K. Kumagai, H. Nakashima, and H. Urata Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J. Am. Coll. Cardiol. 41 2003 2197 2204
23. S.C.R.K. Shroff, J. Sahadevan, and N.L. Martovitz Selective aldosterone blockade is more effective than ACE-inhibition in suppressing inducibility of sustained atrial tachyarrhythmias in the canine rapid ventricular pacing-induced heart failure model Circulation 108 2003 507
24. A. Frustaci, C. Chimenti, and F. Bellocci Histological substrate of atrial biopsies in patients with lone atrial fibrillation Circulation 96 1997 1180 1184
25. M.K. Chung, D.O. Martin, and D. Sprecher C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation Circulation 104 2001 2886 2891
26. R.J. Aviles, D.O. Martin, and C. Apperson-Hansen Inflammation as a risk factor for atrial fibrillation Circulation 108 2003 3006 3010
27. S. Verheule, E. Wilson, and T. Everett Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation Circulation 107 2003 2615 2622
28. A. Shiroshita-Takeshita, G. Schram, and J. Lavoie Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs Circulation 110 2004 2313 2319
29. M.I. Dotani, D.M. Elnicki, and A.C. Jain Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting Am. J. Cardiol. 86 2000 1128 1130 [A6]
30. Y.I.G.S. Ishii, R.B. Schuessler, and J.P. Boineau Inflammation of the atrium following cardiac surgery is associated with inhomogeneity of atrial conduction Circulation 108 2003 IV-646 [No 17]
31. R. Arora, S. Verheule, and L. Scott Arrhythmogenic substrate of the pulmonary veins assessed by high-resolution optical mapping Circulation 107 2003 1816 1821
32. P. Jais, M. Hocini, and L. Macle Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation Circulation 106 2002 2479 2485
33. J.R. Ehrlich, T.J. Cha, and L. Zhang Cellular electrophysiology of canine pulmonary vein cardiomyocytes: Action potential and ionic current properties J. Physiol. 551 2003 801 813
34. J. Kalifa, J. Jalife, and A.V. Zaitsev Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation Circulation 108 2003 668 671
35. M. Haissaguerre, P. Jais, and D.C. Shah Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N. Engl. J. Med. 339 1998 659 666
36. C. Pappone, V. Santinelli, and F. Manguso A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome N. Engl. J. Med. 349 2003 1803 1811
37. C.C. Chou, S. Zhou, and Y. Miyauchi Effects of procainamide on electrical activity in thoracic veins and atria in canine model of sustained atrial fibrillation Am. J. Physiol. Heart Circ. Physiol. 286 2004 H1936 H1945
38. S.A. Chen, M.H. Hsieh, and C.T. Tai Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation Circulation 100 1999 1879 1886
39. K.T.Y. Matsuo, K. Uno, and C.M. Khrestian A new mechanism of sustained atrial fibrillation: Studies in the canine sterile pericarditis model Circulation 98 Suppl 1998 209
40. G. Fenelon, R.K. Shepard, and B.S. Stambler Focal origin of atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure J. Cardiovasc. Electrophysiol. 14 2003 1093 1102
41. K.S.S. Ryu, J. Sahadevan, and N.L. Martovitz Multiple sites of rapid atrial activation as mechanism of sustained atrial fibrillation in dogs with rapid ventricular pacing Heart Rhythm 1 1S 2004 S31
42. J. Sahadevan, K. Ryu, and L. Peltz Epicardial mapping of chronic atrial fibrillation in patients: Preliminary observations Circulation 110 2004 3293 3299
43. D.S. Echt, P.R. Liebson, and L.B. Mitchell Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N. Engl. J. Med. 324 1991 781 788
44. V. Fuster, L.E. Ryden, and R.W. Asinger ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J. 22 2001 1852 1923
45. D.G. Wyse, A.L. Waldo, and J.P. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N. Engl. J. Med. 347 2002 1825 1833
46. T. Meinertz, G.Y. Lip, and F. Lombardi Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] study) Am. J. Cardiol. 90 2002 1300 1306
47. E.L. Pritchett, R.L. Page, and M. Carlson Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation Am. J. Cardiol. 92 2003 941 946
48. R.L. Page, S.J. Connolly, and W.E. Wilkinson Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response Am. Heart J. 143 2002 643 649
49. S.J. Connolly, D.J. Schnell, and R.L. Page Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation Am. J. Cardiol. 88 2001 974 979
50. E.L. Pritchett, R.L. Page, and S.J. Connolly Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. Azimilide supraventricular arrhythmia program 3 (SVA-3) Investigators J. Am. Coll. Cardiol. 36 2000 794 802
51. C.M. Pratt, S.N. Singh, and H.R. Al-Khalidi The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial J. Am. Coll. Cardiol. 43 2004 1211 1216
52. W. Sun, J.S. Sarma, and B.N. Singh Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: Comparison with amiodarone J. Cardiovasc. Pharmacol. 39 2002 677 684
53. A. Varro, J. Takacs, and M. Nemeth Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: Comparison with amiodarone Br. J. Pharmacol. 133 2001 625 634
54. J.M. van Opstal, M. Schoenmakers, and S.C. Verduyn Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome Circulation 104 2001 2722 2727
55. A. Rochetaing, C. Barbe, and P. Kreher Beneficial effects of amiodarone and dronedarone (SR 33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters assessed during reperfusion in isolated rat hearts J. Cardiovasc. Pharmacol. 38 2001 500 511
56. P. Touboul, J. Brugada, and A. Capucci Dronedarone for prevention of atrial fibrillation: A dose-ranging study Eur. Heart J. 24 2003 1481 1487
57. B.N. Singh, S.J. Connolly, and D. Roy The EURIDIS and ADONIS trials: Dronedarone for maintaining sinus rhythm in patients with atrial fibrillation/flutter Circulation 110 2004 [Abstract 3429]
58. I.D. Dukes, and M. Morad Tedisamil inactivates transient outward K+ current in rat ventricular myocytes Am. J. Physiol. 257 1989 H1746 H1749
59. I.D. Dukes, L. Cleemann, and M. Morad Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells J. Pharmacol. Exp. Ther. 254 1990 560 569
60. J.F. Faivre, S. Rouanet, and A. Bril Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes J. Cardiovasc. Pharmacol. 31 1998 551 557
61. S.H. Hohnloser, P. Dorian, and M. Straub Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter J. Am. Coll. Cardiol. 44 2004 99 104
62. R.N. Goldstein, C. Khrestian, and L. Carlsson AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model J. Cardiovasc. Electrophysiol. 15 2004 1444 1450
63. W. Hollander, A.L. Michelson, and R.W. Wilkins Serotonin and antiserotonins. I. Their circulatory, respiratory, and renal effects in man Circulation 16 1957 246 255
64. D.H. Lemessurier, C.J. Schwartz, and R.F. Whelan Cardiovascular effects of intravenous infusions of 5-hydroxytryptamine in man Br. J. Pharmacol. 14 1959 246 250
65. S. Yusuf, N. Al-Saady, and A.J. Camm 5-hydroxytryptamine and atrial fibrillation: How significant is this piece in the puzzle? J. Cardiovasc. Electrophysiol. 14 2003 209 214
66. R. Pino, E. Cerbai, and G. Calamai Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes Cardiovasc. Res. 40 1998 516 522
67. M.M. Rahme, B. Cotter, and E. Leistad Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation Circulation 100 1999 2010 2017
68. A. Goette, M. Arndt, and C. Rocken Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans Circulation 101 2000 2678 2681
69. A. Goette, T. Staack, and C. Rocken Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation J. Am. Coll. Cardiol. 35 2000 1669 1677
70. C.T. Tsai, L.P. Lai, and J.L. Lin Renin-angiotensin system gene polymorphisms and atrial fibrillation Circulation 109 2004 1640 1646
71. E. Vermes, J.C. Tardif, and M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2003 2926 2931
72. L'P.L. Allier, A. Ducharme, and P.F. Keller Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J. Am. Coll. Cardiol. 44 2004 159 164
73. K.C. Ueng, T.P. Tsai, and W.C. Yu Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study Eur. Heart J. 24 2003 2090 2098
74. S. Cardin, D. Li, and N. Thorin-Trescases Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways Cardiovasc. Res. 60 2003 315 325
75. H. Nakashima, K. Kumagai, and H. Urata Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation Circulation 101 2000 2612 2617
76. A.P. Maggioni, R. Latini, and P.E. Carson Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Trial (Val-HeFT) Am. Heart. J. 149 2005 548 557
77. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N. Engl. J. Med. 341 1999 709 717
78. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
79. F. Zannad, F. Alla, and B. Dousset Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales investigators Circulation 102 2000 2700 2706
80. A.H. Briggs, and W.C. Holland Antifibrillatory effects of electrolyte-regulating steroids on isolated rabbit atria Am. J. Physiol. 197 1959 1161 1164
81. E. Coraboeuf, and E. Deroubaix Effect of a spirolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium J. Pharmacol. Exp. Ther. 191 1974 128 138
82. R. Caballero, I. Moreno, and T. Gonzalez Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels Circulation 107 2003 889 895
83. K.M. Yee, S.D. Pringle, and A.D. Struthers Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure J. Am. Coll. Cardiol. 37 2001 1800 1807
84. R.N.K.C. Goldstein, R. Kyungmoo, and D.R. Van Wagoner Prevention of postoperative atrial fibrillation and flutter using steroids (abstract) Pace 26 2003 1058
85. K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc. Res. 62 2004 105 111
86. E.N. Prystowsky, I. Niazi, and A.B. Curtis Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist J. Am. Coll. Cardiol. 42 2003 1098 1102
87. B.B. Lerman, K.A. Ellenbogen, and A. Kadish Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans J. Cardiovasc. Pharmacol. Ther. 6 2001 237 245
88. O. Piot, C. Chauvel, and A. Lazarus Effects of a selective A1-adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation Pacing Clin. Electrophysiol. 21 1998 2459 2464